Dolutegravir (DTG), a second generation integrase inhibitor (INI) proved efficacious and safe in naive and experienced patients in clinical trials. However, real life data on the impact of DTG when combined with abacavir (ABC) and lamivudine (3TC) in virologically suppressed HIV-infected patients are limited.
Lipid profile changed after switch to Dolutegravir+3TC/ABC in HIV-infected patients with undetectable HIV-RNA: results from the SCOLTA cohort
PELLICANO', Giovanni Francesco;
2017-01-01
Abstract
Dolutegravir (DTG), a second generation integrase inhibitor (INI) proved efficacious and safe in naive and experienced patients in clinical trials. However, real life data on the impact of DTG when combined with abacavir (ABC) and lamivudine (3TC) in virologically suppressed HIV-infected patients are limited.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
